Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

The Year Ahead

PV0315_TarenGromLast month we identified 10 mega-trends that we, as well as others, think will impact the industry going forward. One of these trends is the increasing focus on the brain and the research efforts ongoing to understand the mysteries of this three-pound organ. And while scientists have learned more about the brain in the last 10 years than in the last century through the sequencing of the human genome, the development of new tools for mapping neuron connections, and new imaging technologies, medications to effectively and with sustainability manage Alzheimer’s, Parkinson’s, and other neurological diseases for the long term are still proving elusive. Yet, there is hope. As Dr. Deborah Dunsire, CEO of Forum Pharmaceuticals, a company dedicated to translating promising R&D into safe and effective medicines for patients with major brain diseases, believes we’re on a path of tremendous forward movement over the next decade.

And it’s not just companies that are focusing their resources on unraveling the complexity of the more than 100 billion nerves that serve as the center of the nervous system. The BRAIN initiative launched by President Obama in 2013 is guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, that details seven high priority research areas. The long-term outcomes of the initiative include the ability to: target specific human cell types to develop new therapies for neurological and psychiatric disorders; discover circuit-level anatomical differences between healthy and disordered brains; treat neurological and psychiatric disorders based on knowledge of each patient’s own circuitry and neural activity patterns; discover general principles of neural coding, circuit dynamics, and plasticity; understand neural population dynamics associated with perception, learning, memory, emotion, and action; and gain insight into the neural basis of human language, symbolic reasoning, and consciousness.

In each issue this year, we will examine different aspects of this therapeutic category from research trends to patient care to commercialization.
Also in each issue this year, we will continue coverage of the popular oncology series we initiated last year. We will look at the research, products, and other trends that are defining this No. 1 therapeutic category, which is being further defined as hundreds of different diseases.

Finally, in each issue this year we will take a look at different areas of the life-sciences continuum as part of a new Then and Now series to celebrate 15 years of trend coverage in PharmaVOICE. Stay tuned for a special forum in the February issue with contributions from dozens of thought leaders who will talk about the changes they have witnessed in the past 15 years and what’s in store for the industry in the coming years. We look forward to sharing these reflections with you as well as insights from hundreds of thought leaders throughout the year as we continue to address the industry’s most-pressing challenges and greatest opportunities.

Taren Grom
Editor
~~~~~~~~~~~~~~~~~~~~~~~~~

Their word…PV0116_TheirWord

Denise Myshko
Managing Editor

Biomarkers
are critical for today’s personalized approach to drug development.

Robin Robinson
Senior Editor

The type of information payers want and what pharma companies can provide are often worlds apart when assigning value to a drug.

Kim Ribbink
Features Editor

Despite slowing growth rates, Brazil’s pharma market continues to remain strong and attractive to global companies.
~~~~~~~~~~~~~~~~~~~~~~~~~
Masthead

Volume 16 • Number 1
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2016
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Sixteen, Number One

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

 

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK